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While the gold standard for clinical trials is to blind all par-
ties – participants, researchers, and evaluators – to treat-
ment assignment, this is not always a possibility. When
some or all of the above individuals know the treatment
assignment, this leaves the study open to the introduction
of post-randomization biases. In the Strategies to Reduce
Injuries andDevelop Confidence in Elders (STRIDE) trial, we
were presented with the potential for the unblinded clini-
cians administering the treatment, as well as the individuals
enrolled in the study, to introduce ascertainment bias into
some but not all events comprising the primary outcome.
In this manuscript, we present ways to estimate the ascer-
tainment bias for a time-to-event outcome, and discuss its
impact on the overall power of a trial versus changing of
the outcome definition to amore stringent unbiased defini-
tion that restricts attention to measurements less subject
to potentially differential assessment. We found that for
themajority of situations, it is better to revise the definition
to amore stringent definition, as was done in STRIDE, even
though fewer events may be observed.
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1 | MOTIVATION
1.1 | Introduction
Although the gold standard for clinical trials is to blind participants, clinical personnel/researchers, and evaluators
to treatment assignment, not all designs and treatments allow for blinding of participants and/or researchers. For
example, it is not possible to blind participants and clinicians in a trial comparing grouped versus individual treatment for
clinical depression. Under these circumstances, trials have the potential to introduce post-randomization detection or
ascertainment bias, in which the lack of blinding of treatment assignment could lead to bias in the outcome assessment,
either in the form of response bias (participant) or observer bias (researcher). It is thus important to take appropriate
measures tomitigate this type of bias and obtain valid treatment comparisons.
1.2 | Motivating Example
The potential for ascertainment bias surfaced in the Strategies to Reduce Injuries andDevelop Confidence in Elders
(STRIDE) trial[1], funded primarily by the Patient CenteredOutcomes Research Institute with additional support from
theNational Institute on Aging at the National Institutes of Health. Briefly, STRIDEwas a cluster-randomized clinical
trial designed to test amulticomponent intervention vs. usual care to prevent serious fall injuries. The trial enrolled
5,451 patients from 86 clinical practices in 10 healthcare systems over 20months (August 1, 2015 toMarch 31, 2017)
and followed them for up to44months (endingMarch31, 2019). The primary outcomewas time tofirst serious fall injury
(SFI), based on self-report data and subsequent verification through the medical record[2]. The trial was unblinded,
and the intervention was administered by nurse falls caremanagers (FCM)who interactedwith participants enrolled
at intervention sites, but not those at sites randomized to standard of care. Because the initial study definition of a
serious fall injury included seekingmedical attention, there was the potential for interactions with the FCM to create
ascertainment bias by sensitizing patients randomized to the intervention to the potential sequelae of falls (potentially
making themmore likely than control participants to seekmedical attention) and for the FCM to refer participants to
seekmedical attention if they reported a fall. Since this type of referral bias could not occur in the control arm, there
was the potential for more falls to be reported in the intervention arm, leading to a dilution of the treatment effect.
The original protocol definition of the primary outcomewas, “a fall injury leading tomedical attention, including
non-vertebral fractures, joint dislocation, head injury, lacerations, and other major sequelae (e.g., rhabdomyolysis,
internal injuries, hypothermia).” Under this definition, seekingmedical attention was intended to affirm the seriousness
of the injury. Fall-related injuries were classified into two types:
Type 1: Fracture other than thoracic/lumbar vertebral; joint dislocation; or cut requiring closure; and
Type 2: Head injury; sprain or strain; bruising or swelling; or other,
with Type 2 fall-related injuries further divided into the following three subtypes:
Type 2a: Type 2 fall-related injury resulting in an overnight hospitalization;
Type 2b: Type 2 fall-related injury resulting in medical attention but not an overnight hospitalization; and
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Type 2c: Type 2 fall-related injury not resulting in medical attention.
The original protocol definition of the primary outcome counted fall-related injuries of Types 1, 2a, and 2b.
We considered the more serious injuries, Type 1 and Type 2a, less susceptible to potential bias because of their
comparatively definitive nature and severity. But since interacting with the FCM could lead participants to seek
medical attention for less serious injuries, thus converting Type 2c injuries (which are not counted in the original
protocol definition) to Type 2b (which are), there was the potential for the FCM (or participants) to introduce bias in
the intervention arm ascertainment of events. Note that it was not possible to adjudicate Type 2c events (with no
medical attention received, there were nomedical records available to adjudicate), though Types 1, 2a and 2b could
be adjudicated[2], so it was necessary to use self-reported rather than adjudicated events to estimate the degree of
ascertainment bias.
1.3 | Overview
In this article, we examine the situation in which an intervention is expected to affect the risk of an outcome, but the
outcome is operationalized in a way that makes some, but not all, cases in the intervention arm subject to ascertainment
bias. For concreteness, we generally write for the case in which ascertainment bias can produce spurious extra events in
the intervention arm, and a useful framework is to consider three categories of possible intervention outcomes:
Category 1: true outcome events that cannot be contaminated by ascertainment bias (e.g. Type 1 and Type 2a in
STRIDE),
Category 2: true outcome events that can bemimicked by non-outcome events via bias (e.g. Type 2b in STRIDE), and
Category 3: events that should not meet the outcome definition but canmimic Category 2 outcomes via bias (e.g. Type
2c in STRIDE).
Throughout themanuscript, for simplicity, wewill consider the above categories and scenario; however, it should
be noted that in situations where ascertainment bias insteadmasks true outcome events in the intervention arm, the
derivations presented remain applicable, with the event categories defined slightly differently:
Category 1: true outcome events that cannot be contaminated by ascertainment bias,
Category 2: events that shouldmeet the outcome definition but may fail to under bias, and
Category 3: events that should not meet the outcome definition and can bemimicked by Category 2 outcomes via bias.
Furthermore, themathematical development below continues to apply even if both forms of ascertainment bias
are present at once, with Category 2 generally being events that should be included in the outcome but may not be
and Category 3 generally being events that should not be included in the outcome but may be. The key assumption,
elaborated below in Section 2, is that the ascertainment bias acts by appearing to shuffle events between these two
categories.
Given the above event category taxonomy, it is possible to define an alternative outcomedefinition that’s impervious
to ascertainment bias by restricting it to include only Category 1 events. If the hypothesized effect is a risk reduction
while the ascertainment bias masks true Category 2 intervention events, or if the hypothesized hazard ratio is greater
than 1while the ascertainment bias introduces spurious Category 2 intervention events, then the bias is away from the
null, making such a definition change imperative. Ofmore interest is the case where a risk reduction is hypothesized,
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but the ascertainment bias introduces spurious Category 2 intervention events (or a hypothesized hazard ratio greater
than 1with ascertainment bias masking true Category 2 intervention events). Here the bias is toward the null, causing a
loss in power. The alternative definition also results in a loss of power, only it is through a reduction in the number of
observable outcomes by defining amore stringent (i.e., less prone to bias) outcome definition.
While there is an argument to bemade for always choosing an outcome definition that allows the trial to produce an
unbiased estimate of the treatment effect, given the direction of the bias (toward the null), this decisionmay not always
be in the best interest of the clinical trial and its participants, especially for ongoing clinical trials. Stakeholders may be
forced to weigh the impact andmagnitude of the ascertainment bias against the reduction in power from restricting the
outcome definition. And the difficulty is magnified in ongoing trials, when the bodymaking the decision about adapting
the outcome definition will need to be presented information about the severity of ascertainment bias in amanner that
maintains blinding with respect to the treatment effect.
Themethods described in this article weremotivated by a need to perform an interim analysis to assess the level
of ascertainment bias in STRIDE, estimate its effect on power under the original protocol definition, and estimate the
effect on power of revising the outcome definition to include only Type 1 and Type 2a fall-related injuries and to present
the results to a blinded ad hoc advisory committee for a decision about whether to adapt the primary outcome.
The rest of themanuscript is laid out as follows: In Section 2we describe themethods used. We give the overall
approach (Section 2.1), define the assumptions (Section 2.2), and describe the methods for estimating the effect of
ascertainment bias on power (Section 3.1) and themethods for estimating the effect of revising the outcome on power
(Section 2.4). We then present the results of the STRIDE example (Section 3) and perform sensitivity analyses and
additional studies of the results (Section 4) through simulation. Finally, we present a discussion, some limitations, and
potential future directions in Sections 5 and 6.
Note that at the time of the decision regarding adaptation of the STRIDE primary outcome, the plannedmaximum
follow-up timewas 40months (it was later extended to the 44months noted above), so a 40-month trial duration is
used in Sections 3 and 4.
2 | METHODS
2.1 | Overall approach
We consider the scenario in which the outcome of interest is time-to-event, the protocol outcome definition is prone to
ascertainment bias, and the bias will: increase the number of observed events in the intervention arm, in turn increasing
the observed event rate in the intervention arm; and increase the total number of observed events (since the event
rate in the control arm is unaffected), resulting in the hazard ratio (intervention relative to control) moving toward 1
(assuming the intervention is effective).
We calculate power using the log-rank test method of Schoenfeld[3],
Φ(z1−β ) = Φ
(
1
2
√
E |lnH | − z1−α/2
)
,
where E is the total number of events,H is the hazard ratio (intervention relative to control), 1 − β is the power, α is the
type I error rate, andΦ(·) is the cumulative normal probability. Increasing the number of events increases power, but
reducing the impact of the intervention decreases power. Both effects need to be accounted for, therefore, we:
1. Estimate the degree of ascertainment bias in Category 2 intervention events (Section 2.3.1),
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2. Estimate how this bias effects the overall number of intervention events (Section 2.3.1),
3. Use the bias-adjusted number of intervention events to estimate the effective hazard ratio (Section 2.3.2), and
4. Use the bias-adjusted event total and effective hazard ratio to estimate power (Section 2.3.3).
Conversely, if we assume that the true hazard ratio is the same across event types, restricting the outcomedefinition
to Category 1will have no impact on the hazard ratio. Thus, when evaluating a change in the outcome definition, we only
need to account for decreasing the numbers of observed events in both arms (since Category 2 events will no longer be
counted). This is described in Section 2.4.
2.2 | Assumptions
While this article is written for the context of a clinical trial or other two-arm study with a total duration T and a
time-to-first-event outcome in the presence of a semi-competing risk, it is possible to generalize the approach for other
designs and scenarios.
If we assume uniform enrollment over the initial fraction µ of the total study periodT , an outcome hazard of λ
in the control arm, and a competing risk hazard of γ, then for a given hazard ratio H , events in the control (EC ) and
intervention arms (EI ) will be generated (see Appendix A for a derivation) according to
EC =
N ∗
C
λ
λ + γ
(
1 − e
−(1−µ)T (λ+γ) − e−T (λ+γ)
µT (λ + γ)
)
, (1)
EI =
N ∗I Hλ
Hλ + γ
(
1 − e
−(1−µ)T (Hλ+γ) − e−T (Hλ+γ)
µT (Hλ + γ)
)
, (2)
where the control and intervention sample sizes N ∗
C
and N ∗I have been adjusted for factors such as expected loss to
follow-up, design effect/variance inflation, and interim looks (see Section 3).
Tomake the bias problem tractable, wemake several assumptions:
1. The hypothesized hazard ratio,H hyp , is the same for all event categories e (1, 2, and 3, even though Category 3 is
not part of the outcome). It follows (see Appendix B for details) that there is a single constant κ relating true control
and true intervention events such that
universalAlte ∈ {1, 2, 3} : E t r ueI e = κE t r ueCe . (3)
2. Ascertainment bias acts only in the intervention arm and only on Categories 2 and 3, causing some true Category 3
events to become observed intervention Category 2 events and/or vice versa. This implies
E obsI 1 = E
t r ue
I 1 ,
E obsI 2 + E
obs
I 3 = E
t r ue
I 2 + E
t r ue
I 3 ,
and
universalAlte ∈ {1, 2, 3} : E obsCe = E t r ueCe = ECe .
(Since we assume the observed and true events are equal in the control arm, no superscript is needed below for the
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control events.)
2.3 | Estimating the effect of ascertainment bias on power
2.3.1 | Estimating the effect on number of events
We first estimate the degree of ascertainment bias in Category 2 intervention events. Let ρI and ρC be the proportion
of combined Category 2 and 3 events that are observed in Category 2 in the intervention and control arms, respectively,
and let B be the ratio of these proportions, such that:
ρI =
E obs
I 2
E obs
I 2 + E
obs
I 3
(4)
ρC =
EC2
EC2 + EC3
(5)
B =
ρI
ρC
. (6)
Through substitution and some algebra, we find that B can also be defined as the inflation in observed intervention
Category 2 events due to ascertainment bias:
B =
E obs
I 2
E t r ue
I 2
.
It is important to note that B does not provide information about the actual treatment effect and can therefore be
presented to a blinded decision-making panel.
We can therefore express the excess Category 2 events in terms of B and the observed number of events in the
intervention arm:
E excessI 2 = E
obs
I 2 − E t r ueI 2
= (B − 1)E t r ueI 2
= (1 − 1B )E obsI 2 .
Next, we estimate how this bias effects the overall number of intervention events. Let P be the fraction of control
events (Categories 1 and 2) that are in Category 2:
P =
EC2
EC
=
EC2
EC1 + EC2
(7)
By Equation (3), this will also be the expected ratio among the true intervention events, such that
E t r ueI 2 = PE
t r ue
I
E t r ueI 1 = (1 − P )E t r ueI .
Therefore, through substitution and algebra, we obtain E obs
I
as
E obsI = E
t r ue
I [1 + P (B − 1)] = kE t r ueI , (8)
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where
k = 1 + P (B − 1) (9)
is the proportionality factor, and the excess number of events in the intervention arm, E excess
I
, is defined as
E excessI = (k − 1)E t r ueI
= (1 − 1k )E obsI .
Finally, if the true numbers of events are given by equations (1) and (2), the number of observed intervention events
will be
E obsI = kE
t r ue
I =
kN ∗I H
hypλ
H hypλ + γ
(
1 − e
−(1−µ)T (H hypλ+γ) − e−T (H hypλ+γ)
µT (H hypλ + γ)
)
. (10)
2.3.2 | Estimating the effect on the hazard ratio
Working fromEquation (2), we can also express the observednumber of intervention eventsE obs
I
in terms of an effective
hazard ratioH ef f :
E obsI =
N ∗I H
ef f λ
H ef f λ + γ
(
1 − e
−(1−µ)T (H ef f λ+γ) − e−T (H ef f λ+γ)
µT (H ef f λ + γ)
)
. (11)
Combining Equations (10) and (11), we obtain an expression relating the effective hazard ratioH ef f to the hypothesized
hazard ratioH hyp , the control event hazard λ, the competing risk hazard γ, the study durationT , and the recruitment
period fraction µ (but not sample size or other factors that might affect the number of events independent of the hazard
ratio):
H ef f λ
H ef f λ + γ
(
1 − e
−(1−µ)T (H ef f λ+γ) − e−T (H ef f λ+γ)
µT (H ef f λ + γ)
)
=
kH hypλ
H hypλ + γ
(
1 − e
−(1−µ)T (H hypλ+γ) − e−T (H hypλ+γ)
µT (H hypλ + γ)
)
. (12)
This equation does not have a closed-form solution for H ef f , but both Taylor series (expanding in powers of
T (H ef f λ + γ)) and numerical approximations are described in Appendix C. A first-order approximation is
H ef f[1] =
kH hyp(
1 − µ2
)
T (H hypλ + γ)
(
1 − e
−(1−µ)T (H hypλ+γ) − e−T (H hypλ+γ)
µT (H hypλ + γ)
)
,
while to second order,
H ef f[2] =
θ
λ
(
1 −
√
1 − φ2/θ2
)
where
θ =
1
2
[
3
T
(
2 − µ
µ2 − 3µ + 3
)
− γ
]
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and
φ =
1
T
√√(
6
µ2 − 3µ + 3
) (
kH hypλ
H hypλ + γ
) (
1 − e
−(1−µ)T (H hypλ+γ) − e−T (H hypλ+γ)
µT (H hypλ + γ)
)
.
Since the expansion parametermay not be small compared to 1 (e.g., in the STRIDE trial,T (H ef f λ + γ) > T (H hypλ + γ) ≈
0.52), these approximations are best used as starting points for numerical estimation.
Note that when estimating these quantities from observed data, we can compute the cause-specific hazards (λ and
γ) from the observed cause-specific rates (see Appendix D).
2.3.3 | Estimating the overall effect on power
OnceH ef f has been estimated, the projected power can be obtained via:
Φ(z1−βpr ot ) = Φ
(
1
2
√
EC + E
obs
I
lnH ef f  − z1−α/2) , (13)
with EC defined as in Equation (1) and E obsI defined as in Equation (10).
2.4 | Estimating the effect of redefining the outcome on power
If we change our outcome definition to include only Category 1 events, then if the true number of total control events (in
both Categories 1 and 2), EC , is given by Equation (1), the number of control events under the revised definition will be
E r edefC = (1 − P )EC =
(1 − P )N ∗
C
λ
λ + γ
(
1 − e
−(1−µ)T (λ+γ) − e−T (λ+γ)
µT (λ + γ)
)
,
where P is the proportion of control events that are Category 2 (as defined in Equation 7).
Since Category 1 events are not subject to ascertainment bias, there is no longer an effect on the hazard ratio, and
the number of intervention events under the revised definition will be
E r edefI =
(1 − P )N ∗I H hypλ
H hypλ + γ
(
1 − e
−(1−µ)T (H hypλ+γ) − e−T (H hypλ+γ)
µT (H hypλ + γ)
)
= (1 − P )EI ,
with EI taken from Equation (2).
Using these redefined expected events, the projected power can be obtained from the following:
Φ(z1−β r edef ) = Φ
(
1
2
√
E r edef
C
+ E r edef
I
lnH hyp  − z1−α/2) = Φ ( 12√(1 − P )(EC + EI ) lnH hyp  − z1−α/2) . (14)
3 | RESULTS: STRIDE EXAMPLE
This method and the preliminary data obtained from the STRIDE study informed the decision to change the definition of
the primary outcome[4] to avoid impacts of potential ascertainment bias. Following from Section 2, we demonstrate for
the STRIDE trial how to estimate the bias (Section 3.1; calculation of confidence intervals is discussed in Appendix E),
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adjust the sample sizes to obtainN ∗
C
andN ∗I (Section 3.2), estimate the hazards (Section 3.3), and estimate the projected
number of self-reported events (Section 3.4). Since STRIDE adjudicated self-reported outcomes, we present methods
to estimate the projected number of adjudicated events in Section 3.5. Then, in Section 3.6 we calculate the effective
hazard. All of these pieces are necessary to determine the power of the trial under the protocol and revised outcome
definitions in Section 3.7.
3.1 | Estimation of ascertainment bias
Using all available information to determine the degree of observed bias and estimate its effect on study power, we
follow the logic of Section 2.3. In a snapshot of all self-report data taken on February 22, 2018, the control group
reported a total of 253 Type 2b (Category 2) events and 613 Type 2c (Category 3) events, while the intervention group
reported 263 and 526, respectively, total events of these types. Using Equations (4), (5), and (6), our proportions ρ are
thus ρC = 253253+613 = 0.292 and ρI = 263263+526 = 0.333, and our estimate of ascertainment bias is B = ρI /ρC = 1.141 (95%
CI: 0.978–1.304). Therefore, the inflation in observed Category 2 intervention events due to ascertainment bias in the
STRIDE study at the time of data lock was estimated to be 14.1%.
For first events (the primary outcome of interest), the control group reported 215 Type 1, 55 Type 2a (for a total of
270 in Category 1) and 206 Type 2b (Category 2) first events. Using Equations (7) and (9), we can estimate the Category
2 fraction of first events, P = 206270+206 = 0.433 (95% CI: 0.388–0.477; recall from Section 2.3.1 that P is defined in
terms of observed control events, which are assumed free from ascertainment bias), and the estimated biased-induced
inflation, k = 1 + (0.433)(0.141) = 1.061 (95%CI: 0.990–1.132). Hence, we estimate that we are observing 6.1%more
primary outcome events in the intervention arm due to ascertainment bias.
3.2 | Effective sample sizes
As described in Section 2.2, Equations (1) and (2) require effective control and intervention sample sizes that account
for loss to follow-up and the variance inflation/design effect.
We can project the overall proportion lost in aT -month trial to beW = 1− (1−w )T /(12mo) , wherew is the observed
loss rate (consent withdrawals per person-year of follow-up). For STRIDE, withT = 40mo and an observed loss rate of
w = 0.022 (at data lock), we projected the overall proportion lost to beW = 0.071.
We estimated the variance inflation/cluster design effects by calculating the ratios of the variances of the estimates
of the intervention effect parameters from lognormal frailty and unclustered Coxmodels (treating competing events as
censored) using self-reported events under the protocol and revised definitions. At data lock, the variance inflation
factors wereV pr ot = 1.0000 (95% CI: 1.0000–1.0000) under the protocol definition andV r edef = 1.0475 (95% CI:
1.0000–1.1775) under the revised definition.
Finally, effective sample sizes were calculated as N ∗ = N (1 −W )/V . With actual enrollments of NC = 2649 and
NI = 2802, our effective sample sizes were N ∗pr otC = 2459.6 and N ∗pr otI = 2601.6 for the protocol definition and
N ∗r edef
C
= 2348.0 and N ∗r edef
I
= 2483.6 for the revised definition. These adjustments aremade because it is important
to recognize that in a trial with clustering and loss to follow-up, the effective sample size N ∗ will be smaller than the
observed baseline sample size.
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3.3 | Hazards
In the STRIDE snapshot, we observed r pr ot
C
= 0.148 patient-reported control events per person year of follow-up (PYF)
under the protocol definition, r r edef
C
= 0.089 patient-reported control events per PYF under the revised definition,
and d = 0.025 deaths per PYF. Using Equations (28) and (29) from Appendix D, we calculated our observed hazards
to be λpr ot
C
= 0.0135mo−1 and γpr ot = 0.0023mo−1 for the protocol definition and λr edef
C
= 0.0079mo−1 and γr edef =
0.0022mo−1 for the revised definition. Since the revised definition includes only a subset of events from the protocol
definition, the event hazard under the revised definition is smaller, as onewould expect.
3.4 | Projected self-reported events
Using the hypothesized hazard ratio H hyp = 0.8, the trial durationT = 40mo, and the recruitment fraction µ = 0.5
from the STRIDE design, along with the estimated bias inflation k from Section 3.1, effective sample sizes from Section
3.2, and hazards from Section 3.3, we can project the numbers of self-reported control and intervention events under
the protocol and revised definitions. For the protocol definition, we setH = H hyp = 0.8, λ = λpr ot
C
= 0.0135mo−1, and
γ = γpr ot = 0.0023mo−1 and use Equation (1) to project E pr ot ,sr
C
= 789.0 self-reported control events, Equation (2) to
project E pr ot ,sr ,t r ue
I
= 694.0 true self-reported intervention events, and Equation (10) to project E pr ot ,sr ,obs
I
= 736.3
observed self-reported intervention events. For the reviseddefinition,we setH = H hyp = 0.8,λ = λr edef
C
= 0.0079mo−1 ,
and γ = γr edef = 0.0022mo−1 and use Equation (1) to project E r edef ,sr
C
= 476.1 self-reported control events and
Equation (2) to project E r edef ,sr
I
= 412.3 self-reported intervention events.
3.5 | Projected adjudicated outcome events
The primary analysis for STRIDE uses adjudicated rather than self-reported outcomes, so a calculation of projected
power needs to account for some fraction of self-reported events not becoming confirmed outcome events. Though the
data snapshot was taken early in the adjudication process, we used the available information from completed cases to
estimate the overall confirmation fractions under the protocol and revised definitions.
Notably, the fraction of self-reported events confirmed in adjudication (denotedAt where t is the event type) varied
across event types: A1 = 0.966 of Type 1 self-reported events were confirmed, while onlyA2a = 0.667 of Type 2a and
A2b = 0.771 of Type 2b were confirmed. (These fractions were similar across treatment groups.) Since the revised
definition does not include Type 2b events, the proportions of self-reported events of each type differed by definition:
P
pr ot
1 = 0.452, P pr ot2a = 0.116, and P pr ot2b = 0.433 under the protocol definition, while P r edef1 = 0.789 and P r edef2a = 0.211
under the revised.
The overall probabilityA that a self-reported event will be adjudicated a true outcome can be estimated as
A = P r (confirm) =
∑
t∈types
P r (t )P r (confirm |t ) =
∑
t∈types
PtAt ,
so the confirmation probabilities for the two definitions are Apr ot = P pr ot1 A1 + P pr ot2a A2a + P pr ot2b A2b = 0.847 and
Ar edef = P r edef1 A1 + P
r edef
2a A2a = 0.903; note that while the revised definition includes fewer events, those events
are more likely to be confirmed in adjudication. We use these confirmation probabilities to convert the projected
self-reported events into projected adjudicated outcomes: E adj = AE sr . For the protocol definition, E pr ot ,adj
C
= 668.5,
E
pr ot ,t r ue,adj
I
= 588.0, and E pr ot ,obs,adj
I
= 623.9 (i.e., 35.9 [6.1%] extra observed intervention events due to bias-induced
inflation). For the revised definition, E r edef ,adj
C
= 430.0 and E r edef ,adj
I
= 372.4.
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3.6 | Effective hazard ratio under the protocol definition
With H hyp = 0.8, T = 40mo, µ = 0.5, k = 1.061, λ = λpr ot
C
= 0.0135mo−1, and γ = γpr ot = 0.0023mo−1, we solve
Equation (12) numerically using themethods of Appendix C and project a bias-induced dampening of the treatment
effect toH ef f = 0.858.
3.7 | Projected power
Using all of the information from Sections 3.1- 3.6, we can calculate the power of the trial under the protocol and revised
definitions. For the protocol definition, Equation (13) tells us thatΦ(z1−βpr ot ) = Φ
(
1
2
√
668.5 + 623.9 |ln 0.858 | − z .975
)
=
Φ(0.782), corresponding to 78.3% projected power. This is lower than the 88.4% power projected under the revised
definition, following from Equation (14) andΦ(z1−β r edef ) = Φ
(
1
2
√
430.0 + 372.4 |ln 0.8 | − z .975
)
= Φ(1.200). Therefore,
the recommendation based on these results was to revise the primary outcome definition to themore stringent (less
bias prone) definition, as evenwith the loss of events, it would still result in greater trial power.
4 | SIMULATIONS
4.1 | STRIDE sensitivity analyses
In preparing the report for the ad hoc advisory committee, our calculations were based on a hypothesized hazard ratio
and on estimates of ascertainment bias, variance inflation, and adjudication confirmation fraction from a snapshot
of data in hand. However, the actual hazard ratio could be different from the hypothesized value, and the snapshot
estimates could be unstable. To address these concerns, we performed sensitivity analyses to examine the effect on
power, under both definitions, of variations in these hypothesized and estimated quantities.
Four parameters of interest, the hypothesized hazard ratio (H hyp ), ascertainment bias (B ), variance inflation (V ),
and overall adjudication confirmation fraction (A), were varied in sensitivity analyses. For each parameter, the power
calculations of Section 3were repeatedwith that parameter varying across a range of values, holding all other quantities
constant and using the values defined in Section 3. H hyp was varied from 0.70 to 0.90 in increments of 0.002, B was
varied from1.00 to 1.25 in increments of 0.01,V (used as bothV pr ot andV r edef ) was varied from1.0 to 1.5 in increments
of 0.01, andA (used as bothApr ot andAr edef ) was varied from 0.50 to 1.00 in increments of 0.01.
Figure 1 demonstrates the effect of the hypothesized hazard ratio on projected power under both the protocol
and revised outcome definitions. Unsurprisingly, power drops for both definitions as the intervention effect weakens
(hazard ratio approaches 1). If the intervention effect is much stronger than anticipated (hazard ratio below about .75
rather than the hypothesized .8), the choice of outcome definition makes no appreciable difference, but the revised
definition otherwise retainsmore power, with the difference becomingmore pronounced as the intervention effect
weakens.
Figure 2 shows how the size of the bias estimate (B , the degree of inflation for intervention Type 2b events) affects
projected power under both the protocol and revised outcome definitions. For STRIDE, the power loss from dilution
of the treatment effect under the protocol definitionmatches the loss from adopting a narrower outcome definition
at B = 1.09; i.e., introducing a 9% ascertainment bias has the same impact on power as reducing the total number of
observed events by 43% (the fraction of protocol outcome events not counted under the revised definition).
Since there are no satisfactory established methods for estimating the design effect for a cluster-randomized
survival trial, we employed amodel-based estimate of variance inflation in our projections. This is especially important
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F IGURE 1 Effect of the hypothesized hazard ratio (H hyp ) on projected power in STRIDE. NC = 2649, NI = 2802,
T = 40mo, µ = 0.5,w = 0.022,V pr ot = 1.0000,V r edef = 1.0475, r pr ot
C
= 0.148, r r edef
C
= 0.089, d = 0.025,A1 = 0.966,
A2a = 0.667,A2b = 0.771, P pr ot1 = 0.452, P pr ot2a = 0.116, P pr ot2b = 0.433, P r edef1 = 0.789, P r edef2a = 0.211, B = 1.141.
F IGURE 2 Effect of ascertainment bias (B ) on projected power in STRIDE. NC = 2649, NI = 2802,T = 40mo,
µ = 0.5,H hyp = 0.8,w = 0.022,V pr ot = 1.0000,V r edef = 1.0475, r pr ot
C
= 0.148, r r edef
C
= 0.089, d = 0.025,A1 = 0.966,
A2a = 0.667,A2b = 0.771, P pr ot1 = 0.452, P pr ot2a = 0.116, P pr ot2b = 0.433, P r edef1 = 0.789, P r edef2a = 0.211.
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F IGURE 3 Effect of variance inflation (V ) on projected power in STRIDE. NC = 2649, NI = 2802,T = 40mo, µ = 0.5,
H hyp = 0.8,w = 0.022, r pr ot
C
= 0.148, r r edef
C
= 0.089, d = 0.025,A1 = 0.966,A2a = 0.667,A2b = 0.771, P pr ot1 = 0.452,
P
pr ot
2a = 0.116, P pr ot2b = 0.433, P r edef1 = 0.789, P r edef2a = 0.211, B = 1.141.
given the snapshot estimates we obtained could be unstable. Wewere particularly interested in the impact of different
design effects. These results are presented in Figure 3; variance inflation naturally has a negative impact on power, but
with the revised definition performing generally better than the protocol definition, we gain some insurance against the
final design effect being larger than estimated.
Finally, Figure 4 shows the effect of the overall adjudication confirmation fraction. As one would expect, larger
confirmation rates result in greater power. For a given confirmation fraction, the revised definition has greater projected
power, and given that Type 1 events were substantially more likely than Type 2b events to be confirmed (Section 3.5),
the revised definition’s higher overall confirmation rate provides a boost on that axis as well.
4.2 | Additional simulations
We performed several additional simulations to explore how ascertainment bias might impact the effective hazard
ratio and study power across ranges of other parameters. For simplicity, we return to the full-information event space
of Sections 3.1 and 2.4, without the additional complications of variance inflation and event adjudication that were
particular to STRIDE, and calculations parallel those in Section 2.3.3. Parameters held constant in a given simulation
were set to STRIDE-like values: unadjusted sample sizes NC = NI = 1611 (STRIDE’s unadjusted targets) in each arm,
T = 40month trial, 20month enrollment period (µ = 0.5), hypothesized hazard ratioH hyp = 0.8, observed control-arm
first event incidence r = 14.8%per year (counting both Category 1 and Category 2), observed death incidence d = 2.5%
per year, and P = 43.2%of full-definition outcomes in Category 2.
In each section that follows, we vary, independently, the ascertainment bias B , along with one additional parameter.
In Section 4.2.1, we vary the proportion of Category 2 events (P ); and in Section 4.2.2, we vary first the control event
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F IGURE 4 Effect of the adjudication confirmation fraction (A) on projected power in STRIDE. NC = 2649,
NI = 2802,T = 40mo, µ = 0.5,H hyp = 0.8,w = 0.022,V pr ot = 1.0000,V r edef = 1.0475, r pr otC = 0.148, r r edefC = 0.089,
d = 0.025, P pr ot1 = 0.452, P pr ot2a = 0.116, P pr ot2b = 0.433, P r edef1 = 0.789, P r edef2a = 0.211, B = 1.141.
rate (r ) and then the follow-up time.
4.2.1 | Impact of varying the proportion of events prone to bias
The total impact of ascertainment bias arises from two sources: The proportion P of true events that can bemimicked
through bias (i.e., that are in Category 2) and the factor B bywhich the observed number of such events is inflated. In
this simulation, we allowed these two parameters to vary independently; P varied from 0 to 1 and B varied from 0.85 to
1.25, both in increments of .05.
Figure 5 shows how these variations impact the effective hazard ratio (H ef f ). B = 1 indicates no ascertainment
bias and thus no effect on the hazard ratio. As B drops below 1, ascertainment bias reduces rather than increases the
number of observed intervention events, moving the hazard ratio further below 1 and biasing study results against
the null and towards the alternative. For B > 1, the dilution of the treatment effect becomesmore severe as B and P
increase, and in the upper right area of the figure, we see that a combination of more bias-induced event inflation and
more events prone to bias can push the hazard ratio above 1, reversing the apparent direction of the intervention effect.
Figure 6 demonstrates the impact varying P and B have on study power; again, B = 1 indicates no ascertainment
bias and no effect on power. As B drops below 1, study power does increase, but since ascertainment bias is away from
the null, this does not reflect a true improvement in sensitivity. For B > 1, study power decreases as either aspect of bias
(inflation or prevalence) worsens; greater prevalence also leads to a greater reduction in power under the revised (i.e.
more restrictive) definition, as there are fewer unbiased (Category 1) events to retain. Of note, the rebound in power at
the high-P end of the B = 1.25 curve comes when the effective hazard ratio crosses 1 (see Figure 5); beyond that point,
the observed intervention effect becomes opposite to its true direction, with even stronger bias pushing the trial result
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F IGURE 5 Effects of inflation of events prone to bias (B ; curve labels) and proportion of events prone to bias (P ;
x-axis) on the effective hazard ratio (H ef f ). NC = NI = 1611,T = 40mo, µ = 0.5,H hyp = 0.8, r pr ot = 0.148, d = 0.025.
F IGURE 6 Effects of inflation of events prone to bias (B ; curve labels) and proportion of events prone to bias (P ;
x-axis) on projected power. The black dashed curve (no label) shows the projected power for the restricted definition;
this is independent of B . NC = NI = 1611,T = 40mo, µ = 0.5,H hyp = 0.8, r pr ot = 0.148, d = 0.025.
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F IGURE 7 Effects of inflation of events prone to bias (B ; curve labels) and control event rate (r pr ot ; x-axis) on the
effective hazard ratio (H ef f ). NC = NI = 1611,T = 40mo, µ = 0.5,H hyp = 0.8, d = 0.025, P = .432.
further away from the null in the wrong direction.
4.2.2 | Impact of varying the event rate and the trial duration
Figures 7 and 8 demonstrate how changes in the outcome event rate impact the effective hazard ratio and projected
power, respectively, across variations in bias. The control event rate was varied from 0.025 to 0.7 in increments of
0.025, while B was varied from 0.85 to 1.25 in increments of 0.05. In the presence of ascertainment bias, power initially
increases with the event rate, but as the event rate grows, the slope inverts and power is lost as the inflation in observed
intervention events overwhelms the benefit of having more events overall. Eventually, as the inflation in observed
intervention events pushes the effective hazard ratio past 1, power again increases with event rate, but toward a
conclusion opposite to the true intervention effect.
Figures 9 and 10 show how changes in the overall trial duration impact the effective hazard ratio and projected
power, respectively, across varying bias. The enrollment period was held fixed at 20months (for any given simulation,
µ = 20moT withT varying from 20 to 160 months in 5 month increments), so these simulations represent the effect
of varying follow-up time. The effect of extending follow-up is similar to the impact of a higher control event rate:
generating additional events is initially helpful, but in the presence of ascertainment bias, the inflation of intervention
events eventually becomes the dominant factor. Perhaps counterintuitively, it is possible for extending follow-up time
to exacerbate rather than ameliorate the loss of power due to ascertainment bias.
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F IGURE 8 Effects of inflation of events prone to bias (B ; curve labels) and control event rate (r pr ot ; x-axis) on
projected power. The black dashed curve (no label) shows the projected power for the restricted definition; this is
independent of B . NC = NI = 1611,T = 40mo, µ = 0.5,H hyp = 0.8, d = 0.025, P = .432.
F IGURE 9 Effects of inflation of events prone to bias (B ; curve labels) and total trial duration (T ; x-axis) on the
effective hazard ratio (H ef f ). NC = NI = 1611, µ = 20moT ,H hyp = 0.8, r pr ot = 0.148, d = 0.025, P = .432.
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F IGURE 10 Effects of inflation of events prone to bias (B ; curve labels) and total trial duration (T ; x-axis) on
projected power. The black dashed curve (no label) shows the projected power for the restricted definition; this is
independent of B . NC = NI = 1611, µ = 20moT ,H hyp = 0.8, r pr ot = 0.148, d = 0.025, P = .432.
5 | DISCUSSION
Our approach is akin to an interim analysis that uses updated event rates (but not updated estimates of the treatment
effect) to look at power, but with the addition of estimating and accounting for the degree of ascertainment bias in the
outcome. Though the calculations should be performed by an unblinded statistician, the results can be shared with and
evaluated by blinded investigators and decision-makers.
Any bias can impact a study and lead to erroneous results; therefore, it is necessary tomitigate biases. Specifically,
a studywith ascertainment bias prevents investigators from obtaining a true estimate of the treatment effect. As was
shownwith the STRIDE example and through the simulation studies, evenmodest amounts of bias can result in loss
of power. Even more important is that for most scenarios, the power reduction from introducing bias is worse than
the power reduction from creating a stricter outcome definition (i.e., removing events prone to bias from the outcome
definition results in greater efficiency while reducing error). In the STRIDE example, the results would most likely be an
under-powered study. While this would be an unfortunate event, we saw that if the bias is severe enough, we could end
upwith an evenmore detrimental result – concluding a result in the completely opposite direction.
We again note that considering the relative efficiency of broader but biased versus narrower but unbiased outcome
definitions, as we have here, is only appropriate in situations where any potential ascertainment bias is toward the null.
If there is ascertainment bias toward the alternative, restricting the outcome definition is necessary to maintain control
over type I error.
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6 | LIMITATIONS AND FUTURE WORK
The current method requires us to assume that the intervention affects all outcomes equally, including Category
3 events that aren’t included in any version of the outcome definition. It is possible that the intervention operates
selectively on the different types of events, becoming more or less effective for more or less severe events, and the
issuemay be exacerbated if the intervention doesn’t target Category 3 events.
For simplicity, we have assumed uniform enrollment, which is often done in pre-trial power calculations butmay not
be true in practice. To account for a different enrollment scheme, it is possible to return to Equation (16) in Appendix A
and use a different parametric distribution g (τ) of enrollment times. If the resulting integral has a closed-form solution,
it will lead to analogs of Equations (1) and (2) for the numbers of events in each arm, and from there, one can follow the
development of Section 2.3.2 to reach a new version of Equation (12) relatingH ef f toH hyp and k .
While obtaining estimates of the bias parameters B and k is fairly straightforward, we saw in the STRIDE example
that in practice, it is necessary tomeasure or estimatemanymore quantities to obtain estimates of the effective hazard
ratio and the projected power. All of these quantities comewith their own uncertainties and could prove unstable when
the interim data is examined, and systematically propagating uncertainty through the calculations is complicated by the
lack of a closed-form expression forH ef f .
The variance inflation used for the effective sample sizes in the STRIDE example was based onmodel estimates.
There is a gap inmethodology to estimate the design effect for complex survival data, but we areworking onmethods to
be able to do so using an additivemodel.
Finally, we saw that STRIDEwas a complex study and considerable effort was needed to apply thesemethods to it
(such as accounting for clustering and bridging the gap between self-reported and adjudicated events). Similarly, it may
not be easy to generalize thesemethods to other studies. However, we have set up a framework to consider, especially
as the number of pragmatic trials increases and blinding of participants and interventionists is not feasible.
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APPEND ICES
A | NUMBER OF EVENTS
In this appendix, we derive the expected number of events for an outcome with hazard rate λ in the presence of a
competing risk with hazard rate γ. Our starting point is the instantaneous hazard,
f (t ) = λe−t (λ+γ) . (15)
Let the total trial duration be T , the enrollment period be a fraction µ of the overall trial, and τ be the time a
participant enters the trial; that participant’s follow-up time is thenT − τ . If we let g (τ) be the probability distribution
of enrollment times (which can vary from 0 to µT ), the probability of an individual having an outcome of interest is
p =
∫ µT
0
g (τ)
[∫ T −τ
0
λe−t (λ+γ) d t
]
dτ
=
∫ µT
0
g (τ) λ
λ + γ
[
−e−t (λ+γ)
]T −τ
0
dτ
=
λ
λ + γ
∫ µT
0
g (τ)
[
1 − e−(T −τ)(λ+γ)
]
dτ . (16)
From Equation (16), the probability of an individual having an outcome of interest under uniform enrollment g (τ) = 1µT
is
p =
λ
λ + γ
∫ µT
0
1 − e−(T −τ)(λ+γ)
µT
dτ
=
λ
λ + γ
[
τ
µT
− e
−(T −τ)(λ+γ)
µT (λ + γ)
]µT
0
=
λ
λ + γ
(
1 − e
−(1−µ)T (λ+γ) − e−T (λ+γ)
µT (λ + γ)
)
.
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Assuming the distribution of events is binomial, the expected number of events is then
E = Np =
Nλ
λ + γ
Q (λ) (17)
where N is the total number of participants and
Q (z ) = 1 − e
−(1−µ)T (z+γ) − e−T (z+γ)
µT (z + γ) . (18)
Note that N and E can be written as N = NC + NI and E = EC + EI respectively, where NC and EC are the numbers in
the control arm and NI and EI are the numbers in the intervention arm.
B | RELATIONSHIP BETWEEN CONTROL AND INTERVENTION EVENTS
Let the hazards for each event category in the control arm be λ1, λ2, and λ3, and let their sum be ξ = λ1 + λ2 + λ3.
Then, following the development of Appendix Awith fe (t ) = λee−t (ξ+γ) for a specific event category e (e ∈ {1, 2, 3}), the
expected number of control events in Category e is given by
ECe =
NCλe
ξ + γ
Q (ξ) (19)
where NC is the number of individuals in the control arm andQ (ξ) is defined in Equation (18) . Note thatQ (ξ) does not
depend on e .
Under the assumption of a constant hazard ratio across event categories, for the intervention armwe have
universalAlte ∈ {1, 2, 3} : λIe = H hypλe ,
ξI = H hypξ;
then the expected number of type e events in the intervention is given by
EI e =
NIH
hypλe
H hypξ + γ
Q (H hypξ),
whereH hyp is the hypothesized ratio and NI is the number of individuals in the intervention arm.
We can calculate the ratio of expected events in Category e as
EI e
ECe
= κ =
NI
NC
· H hyp · ξ + γ
H hypξ + γ
· Q (H
hypξ)
Q (ξ) ,
which is independent of e .
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C | ESTIMATION OF H e f f
We can rewrite Equation (12) as
Λ
Λ + γ
Q (x ) = k Z , (20)
where
Q (x ) = 1 − e
−(1−µ)x − e−x
µx
, (21)
and
Λ = H ef f λ,
x = T (Λ + γ),
Z =
H hypλ
H hypλ + γ
Q (H hypλ).
Note thatQ (x ) = Q (H ef f λ); compare Equations (18) and (21).
We can then obtain H ef f by finding the root Λ∗ (the expected intervention arm hazard after accounting for the
bias) of the function
f (Λ, x (Λ)) = Λ
Λ + γ
Q (x ) − k Z = 0 (22)
and dividing the root by λ.
C.1 | Numerical approximation
Equation (22) is amenable to solution by Newton’s method, whose iterations are Λn+1 = Λn − f (Λn )/f ′(Λn ).
We build up the total derivative of f via the chain rule:
∂f
∂Λ
=
γ
(Λ + γ)2Q (x ) =
γ
(Λ + γ)2
(
1 − e
−(1−µ)x − e−x
µx
)
,
∂f
∂x
=
Λ
Λ + γ
dQ
dx
=
Λ
Λ + γ
(
1
µx2
) {
x
[
(1 − µ)e−(1−µ)x − e−x
]
+
[
e−(1−µ)x − e−x
]}
,
dx
dΛ
= T =
x
Λ + γ
,
and
df
dΛ
=
∂f
∂Λ
+
∂f
∂x
dx
dΛ
=
1
µx (Λ + γ)2
{
γ
[
µx − e−(1−µ)x + e−x
]
+ Λ
[
x
(
(1 − µ)e−(1−µ)x − e−x
)
+ e−(1−µ)x − e−x
]}
.
The second-order approximation given in Equation (24) below is frequently a suitable starting point Λ0.
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C.2 | Analytical approximation
C.2.1 | Taylor series expansion ofQ
First, we note that if we take the binomial expansion
(a + b)n =
n∑
k=0
(
n
n − k
)
an−k bk =
n∑
k=0
n!
k !(n − k )! an−k bk
andmake the substitutions a = 1 and b = −µ, some algebra leads to
1 − (1 − µ)n+1
µ(n + 1)! =
1
µ(n + 1)!
[
1 −
n+1∑
k=0
(n + 1)!
k !(n + 1 − k )! (−µ)k
]
=
1
µ(n + 1)!
[
−
n+1∑
k=1
(n + 1)!
k !(n + 1 − k )! (−µ)k
]
=
n+1∑
k=1
(−µ)k−1
k !(n − k + 1)!
=
n∑
k=0
(−µ)k
(k + 1)!(n − k )! . (23)
We now build up the Taylor series expansion ofQ (x ) from thewell-known expansion of ex ,
ex =
∞∑
n=0
xn
n! .
e−(1−µ)x − e−x =
∞∑
n=0
1
n!
{(− [1 − µ] x )n − (−x )n }
=
∞∑
n=0
(−1)n [(1 − µ)n − 1]
n! xn
= 0 +
∞∑
n=1
(−1)n [(1 − µ)n − 1]
n! xn .
e−(1−µ)x − e−x
µx
=
∞∑
n=1
(−1)n [(1 − µ)n − 1]
µn! xn−1
=
∞∑
n=1
(−1)n−1 [1 − (1 − µ)n ]
µn! xn−1
=
∞∑
n=0
(−1)n [1 − (1 − µ)n+1]
µ(n + 1)! xn
= 1 +
∞∑
n=1
(−1)n [1 − (1 − µ)n+1]
µ(n + 1)! xn .
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Finally,
Q (x ) = 1 − e
−(1−µ)x − e−x
µx
= −
∞∑
n=1
(−1)n [1 − (1 − µ)n+1]
µ(n + 1)! xn
=
∞∑
n=1
(−1)n+1 [1 − (1 − µ)n+1]
µ(n + 1)! xn
=
∞∑
n=1
(
n∑
k=0
(−1)n+k+1µk
(k + 1)!(n − k )!
)
xn by (23)
=
(
1 − µ2
)
x −
(
1
2 − µ2 + µ
2
6
)
x2 + O(x3).
C.2.2 | First-order approximation
To first order,
Q [1](x ) =
(
1 − µ2
)
x =
(
1 − µ2
)
T (Λ + γ),
and Equation (22) becomes
Λ
Λ + γ
(
1 − µ2
)
T (Λ + γ) − k Z = H ef f λT (1 − µ2 ) − k Z = 0
with solution
H ef f[1] =
k Z
λT
(
1 − µ2
)
=
k
λT
(
1 − µ2
) H hypλ
H hypλ + γ
Q (H hypλ)
=
kH hyp(
1 − µ2
)
T (H hypλ + γ)
(
1 − e
−(1−µ)T (H hypλ+γ) − e−T (H hypλ+γ)
µT (H hypλ + γ)
)
.
If we also look at a first-order approximation forQ (H hypλ), we find that to lowest nontrivial order,
H ef f[1] ≈
kH hyp(
1 − µ2
)
T (H hypλ + γ)
(
1 − µ2
)
T (H hypλ + γ) = kH hyp
as onemight naively expect.
C.2.3 | Second-order approximation
To second order,
Q [2](x ) =
(
1 − µ2
)
x −
(
1
2 − µ2 + µ
2
6
)
x2
=
(
1 − µ2
)
T (Λ + γ) −
(
1
2 − µ2 + µ
2
6
)
T 2(Λ + γ)2,
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and Equation (22) becomes
Λ
Λ + γ
[ (
1 − µ2
)
T (Λ + γ) −
(
1
2 − µ2 + µ
2
6
)
T 2(Λ + γ)2
]
− k Z = 0,
which can be rearranged into the standard quadratic form
Λ2 −

1 − µ2
T
(
1
2 − µ2 + µ
2
6
) − γ Λ +
k Z
T 2
(
1
2 − µ2 + µ
2
6
) = 0
(sinceT is assumed to be positive and 12 − µ2 + µ
2
6 has no real zeroes). If we introduce the quantities
θ =
1
2

1 − µ2
T
(
1
2 − µ2 + µ
2
6
) − γ =
1
2
[
3
T
(
2 − µ
µ2 − 3µ + 3
)
− γ
]
and
φ =
1
T
√
k Z
1
2 − µ2 + µ
2
6
=
1
T
√
6k Z
µ2 − 3µ + 3 ,
this reduces to
Λ2 − 2θΛ + φ2 = 0
with solution
Λ = 12
(
2θ −
√
4θ2 − 4φ2
)
= θ
(
1 −
√
1 − φ2/θ2
)
, (24)
where we’ve chosen the root whichmakes the event rate increase withmore events. Finally, we divide through by λ to
obtain the second-order approximation to the effective hazard,
H ef f[2] =
Λ
λ
=
θ
λ
(
1 −
√
1 − φ2/θ2
)
. (25)
Since this approximation is based on a Taylor series expansion in powers of x = T (Λ + γ), we would expect it to
break down as ΛT or γT grows large. Andwe see that if θ becomes negative, the effective hazard ratio also becomes
negative, which is impossible, so the approximation is clearly invalid unless θ ≥ 0, or
γT ≤ 3(2 − µ)
µ2 − 3µ + 3 .
Further, Equation (25) has real solutions only when θ2 ≥ φ2; since we know θmust be nonnegative andφ is defined to
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be positive, we can further tighten our sanity constraint to θ ≥ φ, or
γT ≤ 3(2 − µ)
µ2 − 3µ + 3 −
√
24k Z
µ2 − 3µ + 3 .
In simulations where this constraint is violated, Λ0 = θ has worked as a starting point for numerical estimation.
D | COMPUTING HAZARDS FROM CAUSE-SPECIFIC RATES
With a control outcome hazard rate λ and a (competing) death hazard rate γ, the instantaneous event and death hazards
are
fe (t ) = λe−t (λ+γ),
fd (t ) = γe−t (λ+γ) .
Let r and d be our observed cause-specific cumulative control event and death rates at 12months. Then
r =
∫ 12mo
0
λe−t (λ+γ)d t = λ
λ + γ
(
1 − e−(12mo)(λ+γ)
)
, (26)
d =
∫ 12mo
0
γe−t (λ+γ)d t = γ
λ + γ
(
1 − e−(12mo)(λ+γ)
)
.
Solving each of these equations for
(
1 − e−(12mo)(λ+γ)
)
/(λ + γ) and equating the results, we find
1 − e−(12mo)(λ+γ)
λ + γ
=
r
λ
=
d
γ
,
giving us a relation between λ and γ,
γ = λ
(
d
r
)
, (27)
and the substitutions
λ + γ = λ
(
r + d
r
)
and
λ
λ + γ
=
r
r + d
.
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Making these substitutions in Equation (26), we obtain
r =
r
r + d
(
1 − e−(12mo)λ(r+d )/r
)
e−λ(12mo)(r+d )/r = 1 − (r + d )
−λ(12mo)
(
r + d
r
)
= ln(1 − r − d )
and finally
λ = −
( r
r + d
) ln(1 − r − d )
12mo . (28)
From Equation (27), we then also have
γ = −
(
d
r + d
) ln(1 − r − d )
12mo . (29)
E | CONFIDENCE INTERVALS FOR BIAS PARAMETERS
Recall that for a function f (x1, x2, . . . , xn ) where the variances and covariances of the arguments are known, the
function’s variance (to first order in the argument variances) is
σ2f =
∑
i
(
∂f
∂xi
)2
σ2xi +
∑
i,j
∂f
∂xi
∂f
∂xj
σxi xj . (30)
We rely on this to estimate the variances of functions of more than one variable.
Our bias estimates flow from the three proportions P , ρI , and ρC , whose variances are all of the form p(1 − p)/D ,
whereD is the denominator of the proportion. We assume no covariance among them.
B is the ratio of ρI to ρC ; Equation (6), Equation (30), and some algebra yield
σ2B = B
2
(
σ2ρI
ρ2
I
+
σ2ρC
ρ2
C
)
.
k in turn depends on B and P ; Equations (9) and (30) plus more algebra yield
σ2k = (B − 1)2σ2P + P 2σ2B .
All the bias information needed for further calculation is encapsulated in k , so if the trial parameters are treated
as given, one can use the upper and lower bounds of a confidence interval around k to determine the bounds of the
corresponding confidence intervals of the number of observed intervention events E obs
I
, the effective hazard ratio
H ef f , and the estimated power under ascertainment bias 1 − β pr ot .
In practice, however, the hazards and effective sample sizes are based on observed outcome, death, and withdrawal
rates and estimated design effects and so are also uncertain. Since there is no closed-form expression for H ef f ,
confidence intervals for the effective hazard ratio and projected power can only be obtained via simulation.
